Author + information
- June K. Pickett, MDa,
- Maulin Shah, MDa,b,c,
- Michael Gillette, PharmDb,
- Peter Jones, MDa,
- Salim Virani, MD, PhDa,b,
- Christie Ballantyne, MDa and
- Vijay Nambi, MD, PhDa,b,d,∗ ()
- aDepartment of Medicine, Baylor College of Medicine, Houston, Texas
- bMichael E DeBakey Veterans Affairs Hospital, Houston, Texas
- cSection of Nephrology, Baylor College of Medicine, Houston, Texas
- dDivision of Atherosclerosis and Vascular Medicine, Methodist DeBakey Heart and Vascular Center, Methodist Hospital, Houston, Texas
- ↵∗Address for correspondence:
Dr. Vijay Nambi, Baylor College of Medicine, 6565 Fannin Street, MS A601/STE B160, Houston, Texas 77030.
A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury. A kidney biopsy was performed and suggested acute tubular injury. The serum creatinine returned to baseline after discontinuation of alirocumab. (Level of Difficulty: Intermediate.)
Dr. Shah has served as principal investigator for a Leonard-Meron Biosciences, Inc-sponsored trial. Dr. Jones has served as a scientific advisory consultant for Esperion and Amarin. Dr. Virani has received research support from the Department of Veterans Affairs, World Heart Federation, Jooma and Tahir Family Honorarium, and serves as Associate Editor for Innovations, acc.org, American College of Cardiology; and is a Steering Committee member, Patient and Provider Assessment of Lipid Management (PALM registry) at the Duke Clinical Research Institute, for which he receives no financial remuneration. Dr. Ballantyne has received grant and research support paid to Baylor Medical College; has received support from Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, Roche Diagnostic, NIH, AHA, and ADA; and has served as consultant for Abbott Diagnostics, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Boehringer Ingelheim, Corvidia, Denka Seiken, Esperion, Gilead, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo. Dr. Nambi has received VA MERIT grant 1I01CX001112-01; and is named on provisional patent no. 61721475 Biomarkers to Improve Prediction of Heart Failure Risk, filed by Baylor College of Medicine and Roche; and is the site principal investigator for a study sponsored by Merck and Amgen. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Case Reports author instructions page.
- Received February 20, 2020.
- Revision received April 24, 2020.
- Accepted April 28, 2020.